GlassScriptPhysician profile
Jie Zhou
NPI 1558937888
$3,818.70
in general payments reported to CMS, 2019-2025
32 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $1,040 · 2023: $1,118 · 2024: $857 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399 · Education: $45.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.27 |
| Education | $45.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $919.19 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $596.93 | 2021-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $354.29 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $345.33 | 2021-2025 | |
| Glaxosmithkline, LLC. | $329.11 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $161.44 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $161.37 | 2022-2024 | Dupixent |
| Axsome Therapeutics, INC. | $153.95 | 2023 | Sunosi |
| Harmony Biosciences LLC | $93.68 | 2022-2024 | Wakix |
| Viatris Specialty LLC | $81.87 | 2025 | Yupelri |
| Mylan Specialty L.P. | $74.40 | 2021-2024 | Yupelri |
| Amgen INC. | $51.90 | 2022-2023 | Tezspire |
| Baxter Healthcare | $46.53 | 2024-2025 | Hillrom - Monarch Airway Clearance System |
| Verona Pharma, INC. | $40.48 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $36.37 | 2024-2025 | Nuzyra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.99 | 2023 | |
| Janssen Pharmaceuticals, INC | $33.19 | 2021-2024 | Xarelto |
| Insmed, INC. | $32.48 | 2021-2022 | |
| Electromed, INC. | $31.27 | 2023 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $23.05 | 2025 | Glassia |
| La Jolla Pharmaceutical Company | $22.02 | 2025 | Giapreza |
| Vifor Pharma, INC. | $21.90 | 2025 | Zemaira |
| Tactile Systems Technology INC | $21.76 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.52 | 2022 | |
| United Therapeutics Corporation | $19.79 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.71 | 2022 | |
| Fisher & Paykel Healthcare INC | $19.52 | 2025 | Fisher & Paykel Healthcare |
| Avadel Cns Pharmaceuticals, LLC | $16.22 | 2025 | Lumryz |
| Rigel Pharmaceuticals, INC. | $14.73 | 2022 | |
| Lilly USA, LLC | $13.82 | 2025 | Zepbound, Mounjaro |
| Pulmonx Corporation | $13.55 | 2024 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Genentech USA, INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jie Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.